Literature DB >> 12432948

The cannabinoid receptors.

Allyn C Howlett1.   

Abstract

Cannabinoid receptors were named because they have affinity for the agonist delta9-tetrahydrocannabinol (delta9-THC), a ligand found in organic extracts from Cannabis sativa. The two types of cannabinoid receptors, CB1 and CB2. are G protein coupled receptors that are coupled through the Gi/o family of proteins to signal transduction mechanisms that include inhibition of adenylyl cyclase, activation of mitogen-activated protein kinase, regulation of calcium and potassium channels (CB1 only), and other signal transduction pathways. A class of the eicosanoid ligands are relevant to lipid-mediated cellular signaling because they serve as endogenous agonists for cannabinoid receptors, and are thus referred to as endocannabinoids. Those compounds identified to date include the eicosanoids arachidonoylethanolamide (anandamide), 2-arachidonoylglycerol and 2-arachidonylglyceryl ether (noladin ether). Several excellent reviews on endocannabinoids and their synthesis, metabolism and function have appeared in recent years. This paper will describe the biological activities, pharmacology, and signal transduction mechanisms for the cannabinoid receptors, with particular emphasis on the responses to the eicosanoid ligands.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12432948     DOI: 10.1016/s0090-6980(02)00060-6

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  128 in total

Review 1.  Efficacy in CB1 receptor-mediated signal transduction.

Authors:  Allyn C Howlett
Journal:  Br J Pharmacol       Date:  2004-08       Impact factor: 8.739

2.  Crosstalk between the brain and bone.

Authors:  Laura Masi
Journal:  Clin Cases Miner Bone Metab       Date:  2012-05-29

Review 3.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 4.  Endocannabinoids at the synapse a decade after the dies mirabilis (29 March 2001): what we still do not know.

Authors:  Bradley E Alger
Journal:  J Physiol       Date:  2012-01-30       Impact factor: 5.182

5.  Endocannabinoids and their implications for epilepsy.

Authors:  Bradley E Alger
Journal:  Epilepsy Curr       Date:  2004 Sep-Oct       Impact factor: 7.500

6.  Forebrain-specific inactivation of Gq/G11 family G proteins results in age-dependent epilepsy and impaired endocannabinoid formation.

Authors:  Nina Wettschureck; Mario van der Stelt; Hiroshi Tsubokawa; Heinz Krestel; Alexandra Moers; Stefania Petrosino; Günther Schütz; Vincenzo Di Marzo; Stefan Offermanns
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

7.  Cannabinoid Receptors, Mental Pain and Suicidal Behavior: a Systematic Review.

Authors:  Laura Colino; Javier Herranz-Herrer; Elena Gil-Benito; Teresa Ponte-Lopez; Pablo Del Sol-Calderon; Maria Rodrigo-Yanguas; María Gil-Ligero; Antonio J Sánchez-López; Jose de Leon; Hilario Blasco-Fontecilla
Journal:  Curr Psychiatry Rep       Date:  2018-03-15       Impact factor: 5.285

Review 8.  Medical Cannabis for Older Patients.

Authors:  Amir Minerbi; Winfried Häuser; Mary-Ann Fitzcharles
Journal:  Drugs Aging       Date:  2019-01       Impact factor: 3.923

Review 9.  Involvement of the endocannabinoid system in the neurobehavioural effects of stress and glucocorticoids.

Authors:  Matthew N Hill; Bruce S McEwen
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-11-10       Impact factor: 5.067

10.  Obesity-related dyslipidemia associated with FAAH, independent of insulin response, in multigenerational families of Northern European descent.

Authors:  Yi Zhang; Gabriele E Sonnenberg; Tesfaye Mersha Baye; Jack Littrell; Jennifer Gunnell; Ann DeLaForest; Erin MacKinney; Cecilia J Hillard; Ahmed H Kissebah; Michael Olivier; Russell A Wilke
Journal:  Pharmacogenomics       Date:  2009-12       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.